Alirocumab and Reverse Cholesterol Transport

NCT03014830 PHASE1 COMPLETED

Alirocumab is an injectable treatment for elevated blood cholesterol. The hypothesis of this study is that it also increases cholesterol excretion from the body into the stool, a process sometimes called reverse cholesterol transport. A cholesterol metabolic study will be done before and after 6 weeks of alirocumab treatment. If alirocumab increases reverse cholesterol transport, it is possible that this action provides additional protection from cardiovascular disease.

Details

Lead sponsor	Washington University School of Medicine
Phase	PHASE1
Status	COMPLETED
Enrolment	28
Start date	Thu Jun 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Jul 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Atherosclerosis
• Coronary Heart Disease

Interventions

• Alirocumab
• Placebos

Countries

United States